Company profile BMEA

Biomea Fusion Inc
Description of the company is not available.
Quarter analysis & expected interestLast update: February 08 2024 17:04:58.

After 39 days of this quarter the interest is at 64.0. Based on that we can calculate that during remaining 52 days it will total up to 149.0.
Biomea Fusion expected interest is significantly lower compared to same quarter last year (-45.6%) but similar to previous quarter.

YearQ1Q2Q3Q4
20190
52
inf% QoQ
72
38.5% QoQ
91
26.4% QoQ
2020 60
inf% YoY -34.1% QoQ
40
-23.1% YoY -33.3% QoQ
40
-44.4% YoY 0.0% QoQ
94
3.3% YoY 135.0% QoQ
2021 24
-60.0% YoY -74.5% QoQ
57
42.5% YoY 137.5% QoQ
55
37.5% YoY -3.5% QoQ
74
-21.3% YoY 34.5% QoQ
2022 29
20.8% YoY -60.8% QoQ
116
103.5% YoY 300.0% QoQ
84
52.7% YoY -27.6% QoQ
143
93.2% YoY 70.2% QoQ
2023 274
844.8% YoY 91.6% QoQ
268
131.0% YoY -2.2% QoQ
99
17.9% YoY -63.1% QoQ
212
48.3% YoY 114.1% QoQ
2024 64
-76.6% YoY -69.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Biomea Fusion search interestLast update: February 08 2024 17:04:58.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 17:04:59.

The average 5 years interest of Biomea Fusion was 7.46 per week.
The last year interest of Biomea Fusion compared to the last 5 years has changed by 111.66%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 243.26%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 17:05:03.

After 39 days of this quarter the interest is at 26.0. Based on that we can calculate that during remaining 52 days it will total up to 61.0.
BMF-219 expected interest is significantly higher compared to same quarter last year (+inf%) but similar to previous quarter.

YearQ1Q2Q3Q4
201952
207
298.1% QoQ
357
72.5% QoQ
187
-47.6% QoQ
2020 159
205.8% YoY -15.0% QoQ
47
-77.3% YoY -70.4% QoQ
26
-92.7% YoY -44.7% QoQ
114
-39.0% YoY 338.5% QoQ
2021 264
66.0% YoY 131.6% QoQ
118
151.1% YoY -55.3% QoQ
100
284.6% YoY -15.3% QoQ
48
-57.9% YoY -52.0% QoQ
2022 76
-71.2% YoY 58.3% QoQ
100
-15.3% YoY 31.6% QoQ
79
-21.0% YoY -21.0% QoQ
132
175.0% YoY 67.1% QoQ
2023 0
-100.0% YoY -100.0% QoQ
97
-3.0% YoY inf% QoQ
296
274.7% YoY 205.2% QoQ
73
-44.7% YoY -75.3% QoQ
2024 26
inf% YoY -64.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and BMF-219 search interestLast update: February 08 2024 17:05:02.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 17:05:04.

The average 5 years interest of BMF-219 was 9.8 per week.
The last year interest of BMF-219 compared to the last 5 years has changed by -3.47%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -38.73%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Biomea Fusion clinical-stage biopharmaceutical to provide analysis

Correlation between past revenue and Biomea Fusion clinical-stage biopharmaceutical search interest

There is not enough data for Biomea Fusion clinical-stage biopharmaceutical to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Biomea Fusion clinical-stage biopharmaceutical to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Biomea Fusion menin inhibitor to provide analysis

Correlation between past revenue and Biomea Fusion menin inhibitor search interest

There is not enough data for Biomea Fusion menin inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Biomea Fusion menin inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Biomea Fusion liquid and solid tumors to provide analysis

Correlation between past revenue and Biomea Fusion liquid and solid tumors search interest

There is not enough data for Biomea Fusion liquid and solid tumors to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Biomea Fusion liquid and solid tumors to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Biomea Fusion type 2 diabetes to provide analysis

Correlation between past revenue and Biomea Fusion type 2 diabetes search interest

There is not enough data for Biomea Fusion type 2 diabetes to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Biomea Fusion type 2 diabetes to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Biomea Fusion Redwood City, California to provide analysis

Correlation between past revenue and Biomea Fusion Redwood City, California search interest

There is not enough data for Biomea Fusion Redwood City, California to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Biomea Fusion Redwood City, California to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 17:05:09.

After 39 days of this quarter the interest is at 67.0. Based on that we can calculate that during remaining 52 days it will total up to 156.0.
Biomea Fusion -stock -company expected interest is significantly lower compared to same quarter last year (-41.6%) but similar to previous quarter.

YearQ1Q2Q3Q4
201966
21
-68.2% QoQ
114
442.9% QoQ
0
-100.0% QoQ
2020 28
-57.6% YoY inf% QoQ
72
242.9% YoY 157.1% QoQ
188
64.9% YoY 161.1% QoQ
224
inf% YoY 19.1% QoQ
2021 24
-14.3% YoY -89.3% QoQ
222
208.3% YoY 825.0% QoQ
160
-14.9% YoY -27.9% QoQ
89
-60.3% YoY -44.4% QoQ
2022 73
204.2% YoY -18.0% QoQ
117
-47.3% YoY 60.3% QoQ
91
-43.1% YoY -22.2% QoQ
156
75.3% YoY 71.4% QoQ
2023 267
265.8% YoY 71.2% QoQ
327
179.5% YoY 22.5% QoQ
152
67.0% YoY -53.5% QoQ
200
28.2% YoY 31.6% QoQ
2024 67
-74.9% YoY -66.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Biomea Fusion -stock -company search interestLast update: February 08 2024 17:05:09.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 17:05:12.

The average 5 years interest of Biomea Fusion -stock -company was 10.18 per week.
The last year interest of Biomea Fusion -stock -company compared to the last 5 years has changed by 86.25%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 330.91%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for BMEA
Earnings date: 2024-02-26 After close
Company name: Biomea Fusion Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-14T12:51:02.744574202Z

Analyst Upgrades
Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target

2026-10-14T10:21:47.529807677Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target

2026-10-13T16:30:00-04:00

Earnings Call Transcripts
Biomea Fusion BMF-650 (GLP-131) Phase I Topline Results Conference Call - BIOMEA FUSION INC

2026-10-13T13:08:01-07:00

GlobeNewswire
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

2026-10-12T13:30:08-07:00

GlobeNewswire
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

2026-10-07T15:00:24.999513367Z

Analyst Upgrades
Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10

2026-09-03T05:00:00-07:00

GlobeNewswire
Biomea Fusion to Participate in Upcoming Investor Conferences

2026-08-24T04:00:00-07:00

GlobeNewswire
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

2026-08-13T04:00:00-07:00

GlobeNewswire
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

2026-08-05T13:05:00-07:00

GlobeNewswire
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

2026-06-05T23:32:00Z

GlobeNewswire
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

2026-06-04T08:10:00-04:00

Earnings Call Transcripts
JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - BIOMEA FUSION INC

2026-06-03T12:00:00Z

GlobeNewswire
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

2026-05-12T20:05:00Z

GlobeNewswire
Biomea Fusion to Participate at Upcoming Investor Conferences

2026-05-11T20:54:51Z

GlobeNewswire
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights